Trinity biotech announces q3 2021 results, the entry into a $81,250,000 loan facility to refinance the company's exchangeable senior notes and agreements to repurchase outstanding exchangeable senior notes

Dublin, dec. 15, 2021 (globe newswire) -- trinity biotech plc (nasdaq: trib) (the “company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended september 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the company's subsidiary, trinity biotech investment limited (the “notes”), and exchange agreements for over 99.7% of the outstanding notes, all subject to certain conditions precedent.
TRIB Ratings Summary
TRIB Quant Ranking